While PDA itself has not yet undergone human trials, its structural analog BPC-157 has been evaluated for safety and pharmacokinetics in clinical settings
10.1038/jhg.2016.20 19
Moreover, it reduces the release of the glucagon hormone, which increases blood sugar, and helps maintain balanced levels
Ipamorelin wirkt dabei als Agonist, indem es an spezifische Rezeptoren bindet und gezielt die Sekretion von Wachstumshormon stimuliert
Comparative studies suggest that muscle loss with GLP-1 medications is proportionate to other weight loss methods when matched for total weight lost
[DOI] [PubMed] [Google Scholar] 50.Mosenzon O, Blicher TM, Rosenlund S, Eriksson JW, Heller S, Hels OH, et al